MCID: PHB001
MIFTS: 34

Phobic Disorder malady

Categories: Mental diseases

Aliases & Classifications for Phobic Disorder

Aliases & Descriptions for Phobic Disorder:

Name: Phobic Disorder 12 14
Phobic Anxiety Disorder 69

Classifications:



Summaries for Phobic Disorder

Disease Ontology : 12 An anxiety disorder where fear and anxiety are triggered by a specific stimulus or situation.

MalaCards based summary : Phobic Disorder, also known as phobic anxiety disorder, is related to social phobia and phobia, specific. An important gene associated with Phobic Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Norepinephrine and Citalopram have been mentioned in the context of this disorder. Related phenotype is nervous system.

Related Diseases for Phobic Disorder

Diseases related to Phobic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
id Related Disease Score Top Affiliating Genes
1 social phobia 11.5
2 phobia, specific 10.8
3 agoraphobia 10.8
4 antisocial personality disorder 10.3 HTR1A PIR
5 conjunctival pigmentation 10.2 MAOA SLC6A4
6 dry eye syndrome 10.2 HTR1A SLC6A4
7 pyromania 10.2 MAOA SLC6A4
8 anodontia 10.2 HTR1A SLC6A4
9 apperceptive agnosia 10.2 HTR1A SLC6A4
10 colorectal adenocarcinoma 10.2 MAOA SLC6A4
11 strongyloidiasis 10.2 MAOA SLC6A4
12 waardenburg's syndrome 10.2 HTR1A SLC6A4
13 intrahepatic gall duct cancer 10.2 MAOA SLC6A4
14 luxation of globe 10.2 HTR1A SLC6A4
15 neurogenic bladder 10.2 MAOA PIR SLC6A4
16 renpenning syndrome 10.1 HTR1A MAOA SLC6A4
17 tinea pedis 10.1 HTR1A MAOA SLC6A4
18 chronic eosinophilic pneumonia 10.1 HTR1A MAOA SLC6A4
19 chronic cervicitis 10.1 AMY1A MAOA
20 hypoglycemic coma 10.1 HTR1A MAOA SLC6A4
21 multiple personality disorder 10.1 HTR1A MAOA SLC6A4
22 hepatitis b reinfection following liver transplantation 10.1 HTR1A MAOA SLC6A4
23 keratosis 10.1 HTR1A MAOA SLC6A4
24 cecal benign neoplasm 10.1 HTR1A MAOA SLC6A4
25 lichen disease 10.1 HTR1A MAOA SLC6A4
26 retinoblastoma 10.1 HTR1A MAOA SLC6A4
27 benign epilepsy with centrotemporal spikes 10.1 HTR1A MAOA SLC6A4
28 personality disorder 10.1 HTR1A MAOA SLC6A4
29 microcephaly 13, primary, autosomal recessive 10.1 HTR1A MAOA SLC6A4
30 hypereosinophilic syndrome 10.1 MAOA OPRK1 SLC6A4
31 atrial fibrillation, familial, 10 10.1 HTR1A MAOA SLC6A4
32 primary angle-closure glaucoma 10.1 HTR1A SLC6A4
33 mastitis 10.1 NBAS PIR
34 transmitted_by 10.1 OPRK1 SLC6A4
35 cytomegalic congenital adrenal hypoplasia 10.1 MAOA SLC6A4
36 ornithosis 10.1 MAOA PTK7 SLC6A4
37 schizoid personality disorder 10.1 AMY1A PIR SLC6A4
38 ellis-van creveld syndrome 10.0 HTR1A MAOA SLC6A4
39 postencephalitic parkinson disease 10.0 HTR1A MAOA RGS2 SLC6A4
40 cholestasis-lymphedema syndrome 10.0 CTU2 MAOA NBAS
41 preeclampsia/eclampsia 5 10.0 HTR1A MAOA OPRK1 SLC6A4
42 mandibular cancer 10.0 HTR1A SLC6A4
43 hepatitis d 9.8 HTR1A MAOA PTK7 RGS2 SLC6A4
44 alcohol dependence 9.7
45 anorexia nervosa 9.7
46 panic disorder 9.7
47 substance dependence 9.7
48 fechtner syndrome 9.6 CCKBR HTR1A MAOA PTK7 SLC6A4
49 kidney pelvis papillary carcinoma 9.4 CCKBR HTR1A MAOA OPRK1 PIR PTK7
50 adult brainstem astrocytoma 8.6 AMY1A CCKBR CTU2 HTR1A MAOA NBAS

Graphical network of the top 20 diseases related to Phobic Disorder:



Diseases related to Phobic Disorder

Symptoms & Phenotypes for Phobic Disorder

MGI Mouse Phenotypes related to Phobic Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.17 CCKBR HTR1A MAOA OPRK1 PTK7 RGS2

Drugs & Therapeutics for Phobic Disorder

Drugs for Phobic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
2
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
3
Cycloserine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68-41-7 401 6234
4
Ethanol Approved Phase 4,Phase 2 64-17-5 702
5
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
6
Tiagabine Approved Phase 4 115103-54-3 60648
7 Piracetam Approved Phase 4,Phase 2 7491-74-9
8
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3 525-66-6 4946
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
11
Sertraline Approved Phase 4,Phase 3,Phase 2 79617-96-2 68617
12
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
13
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
14
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
15
Acetylcholine Approved Phase 4 51-84-3 187
16
Topiramate Approved Phase 4 97240-79-4 5284627
17
Vortioxetine Approved Phase 4 508233-74-7 9966051
18
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
19
Serotonin Phase 4,Phase 2,Phase 3,Phase 1 50-67-9 5202
20 Muscarinic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
21 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1
22 Serotonin 5-HT1 Receptor Agonists Phase 4
23 Cholinergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
24 Serotonin Agents Phase 4,Phase 2,Phase 3,Phase 1
25 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
26 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
27 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
28 Parasympatholytics Phase 4,Phase 2,Phase 3,Phase 1
29 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 3,Phase 1
34 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Renal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
39 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Phase 1
41 Quetiapine Fumarate Phase 4,Phase 3,Phase 2,Early Phase 1 111974-72-2
42 Desvenlafaxine Succinate Phase 4 386750-22-7
43 Analgesics Phase 4,Phase 3,Phase 2,Early Phase 1
44 Adrenergic Agents Phase 4,Phase 3,Phase 2
45 Serotonin Antagonists Phase 4,Phase 2
46 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 3
47 GABA Agents Phase 4,Phase 2,Phase 1
48 GABA Agonists Phase 4
49 GABA Modulators Phase 4,Phase 1
50 Adrenergic Antagonists Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 317)
id Name Status NCT ID Phase
1 The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment Completed NCT00407199 Phase 4
2 RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo Completed NCT00184106 Phase 4
3 D-Cycloserine Enhancement of Exposure in Social Phobia Completed NCT00633984 Phase 4
4 Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder Completed NCT00282828 Phase 4
5 Nefazodone in the Treatment of Social Phobia Completed NCT00231348 Phase 4
6 Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents Completed NCT01160588 Phase 4
7 Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder Completed NCT00872131 Phase 4
8 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder Completed NCT01316302 Phase 4
9 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4
10 Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder Completed NCT00767871 Phase 4
11 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4
12 Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder Completed NCT00208741 Phase 4
13 Escitalopram in Patients With Social Anxiety Disorder Completed NCT00902226 Phase 4
14 Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults Completed NCT01224067 Phase 4
15 Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder Completed NCT00190879 Phase 4
16 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Completed NCT00177008 Phase 4
17 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4
18 Acamprosate in Alcoholics With Comorbid Anxiety or Depression Completed NCT00330174 Phase 4
19 Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP) Recruiting NCT00182455 Phase 4
20 Brief Intervention to Reduce Fear of Public Speaking Recruiting NCT02790736 Phase 4
21 A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder Recruiting NCT03078270 Phase 4
22 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Active, not recruiting NCT00182533 Phase 4
23 Comparison of Routine IM Influenza Immunization and Administration by Jet-injector in Healthy Young Adults Active, not recruiting NCT03150537 Phase 4
24 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Active, not recruiting NCT02294305 Phase 4
25 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Active, not recruiting NCT01863459 Phase 4
26 Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias Terminated NCT01623583 Phase 4
27 Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice Unknown status NCT01388231 Phase 2, Phase 3
28 Study of Escitalopram in the Treatment of Specific Phobia Completed NCT00121069 Phase 2, Phase 3
29 Treatment of Childhood Social Phobia Completed NCT00043537 Phase 3
30 Residential Cognitive and Interpersonal Therapy for Social Phobia Completed NCT00326430 Phase 2, Phase 3
31 A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy Completed NCT00564967 Phase 3
32 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
33 Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia Completed NCT00515879 Phase 3
34 Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety Completed NCT00958880 Phase 3
35 Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants Completed NCT00734422 Phase 2, Phase 3
36 Long-term Study Of Paroxetine in Women and Men Completed NCT00264654 Phase 3
37 Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants Completed NCT02007694 Phase 2, Phase 3
38 D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia Completed NCT01102803 Phase 3
39 Social Anxiety Disorder Study Of Paroxetine Completed NCT00318669 Phase 3
40 Flushing in Social Anxiety Disorder on Seroquel Completed NCT00773162 Phase 3
41 Child and Adolescent Anxiety Disorders (CAMS) Completed NCT00052078 Phase 3
42 Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder Completed NCT00260533 Phase 2, Phase 3
43 Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder Completed NCT00074802 Phase 3
44 Quetiapine in Social Anxiety Disorder Completed NCT00215254 Phase 2, Phase 3
45 Treatment for Anxiety in Children Completed NCT00000389 Phase 3
46 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
47 St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD) Completed NCT00118833 Phase 2, Phase 3
48 Virtual Reality Exposure Therapy in Agoraphobic Participants Completed NCT00734370 Phase 2, Phase 3
49 Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) Completed NCT02622958 Phase 3
50 Treatment of Panic Disorder: Long Term Strategies Completed NCT00000368 Phase 3

Search NIH Clinical Center for Phobic Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Phobic Disorder

Anatomical Context for Phobic Disorder

Publications for Phobic Disorder

Articles related to Phobic Disorder:

(show all 12)
id Title Authors Year
1
Genetic association between BDNF gene polymorphisms and phobic disorders: a case-control study among mainland Han Chinese. ( 21295349 )
2011
2
Validation of the diagnoses of panic disorder and phobic disorders in the US National Comorbidity Survey Replication Adolescent (NCS-A) supplement. ( 21495110 )
2011
3
The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomized controlled trial. ( 15897725 )
2005
4
Temporal relationship between the age of onset of phobic disorders and development of substance dependence in adolescent psychiatric patients. ( 15283954 )
2004
5
A polymorphic genomic duplication on human chromosome 15 is a susceptibility factor for panic and phobic disorders. ( 11509185 )
2001
6
The longitudinal study of phobic disorder in a community sample from early to late adolescence. ( 11018436 )
2000
7
Social and personal resources and the prevalence of phobic disorder in a community population. ( 10883724 )
2000
8
Phobic disorder, psychotherapy, and risk-taking: an economic perspective. ( 10180917 )
1998
9
Frequency of phobic disorder in a community sample of young adolescents. ( 7559315 )
1995
10
Role of thymic hormones in neuroimmunomodulation. Their use in patients with phobic disorders. ( 1776534 )
1991
11
Administration of thymopentin to patients with phobic disorders improves depressed phagocytic functions. ( 2092042 )
1990
12
Is anorexia nervosa a phobic disorder? A psychophysiological enquiry. ( 7417632 )
1980

Variations for Phobic Disorder

Copy number variations for Phobic Disorder from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 94765 15 70400000 76100000 Copy number LOXL1 phobic disorder

Expression for Phobic Disorder

Search GEO for disease gene expression data for Phobic Disorder.

Pathways for Phobic Disorder

GO Terms for Phobic Disorder

Cellular components related to Phobic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.02 CCKBR HTR1A OPRK1 PTK7 SLC6A4

Biological processes related to Phobic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 vasoconstriction GO:0042310 9.26 HTR1A SLC6A4
2 sensory perception GO:0007600 9.16 CCKBR OPRK1
3 behavior GO:0007610 8.96 HTR1A OPRK1
4 digestion GO:0007586 8.8 AMY1A CCKBR PIR

Sources for Phobic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....